AngioDynamics Reports 'Durable Oncologic Control' in Study of NanoKnife for Intermediate-Risk Prostate Cancer
AngioDynamics (ANGO) shares were up close to 3% in Wednesday trading after it said two-year results from the PRESERVE pivotal trial demonstrated "durable oncologic control and a sustained safety profile" for its NanoKnife System for prostate tissue ablation in patients with intermediate-risk prostate cancer.The study is evaluating focal irreversible electroporation using the NanoKnife System in 121 patients with Gleason Grade Group 2-3 intermediate-risk prostate cancer.The company's NanoKnife System, which uses irreversible electroporation, is intended to reduce quality of life complications, according to a study archived by the National Institutes of Health's National Library of Medicine.Shares of AngioDynamics were up close to 3% in Wednesday trading.Price: $10.94, Change: $+0.04, Percent Change: +0.37%
